Compare Peloton Interactive Inc (PTON) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Peloton Interactive Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Peloton Interactive Inc trades at $4.92 (market cap $2.16B), while State Street SPDR S&P Biotech ETF trades at $149.93 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 4.7× Peloton Interactive Inc's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Peloton Interactive Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Peloton Interactive Inc for 37 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| PTON | XBI | |
|---|---|---|
Market Cap | $2.16B | $10.11B |
Volume | 11,369,487 | 12,903,266 |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $7.86 | $169.55 |
52-Week Low | $3.71 | $104.99 |
Typical Hold Time | 37 Days | 37 Days |
Enterprise Value | $2.66B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Peloton (PTON) trades at $4.85, down 0.41% on the day, amid a bearish technical signal and mixed earnings history. The company reported its first full-year net profit in 2026 with a 2.58% net income margin, yet revenue has declined from $3.6B in 2022 to $2.4B in 2026. Positive cash flow trends and a new product launch, including a foldable treadmill, aim to revive growth, but negative shareholder equity and high debt levels persist as concerns.
The outlook hinges on execution of the turnaround strategy; upside exists if new products boost subscriptions, but risks include persistent subscriber declines and high leverage. Analyst consensus is a Buy with a $8.00 price target, suggesting significant potential appreciation from current levels if operational improvements continue.
XBI trades at $150.23, down 0.44% on the day, with a bearish technical signal driven by moving averages and oscillators. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts. Recent news highlights sector optimism from cancer vaccine breakthroughs and improved capital access, though the ETF carries higher volatility than broader healthcare funds.
The outlook is mixed: strong sector tailwinds from innovation and consolidation support growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst sentiment is neutral with 100% hold ratings, suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Peloton Interactive Inc
Peloton Interactive Inc operates an interactive fitness platform. It operates its business in two reportable segments: Connected Fitness Products and Subscription. Connected Fitness Product revenue consists of sales of bike and tread and related accessories, associated fees for delivery and installation, and extended warranty agreements. Subscription revenue consists of revenue generated from monthly Connected Fitness Subscription and Digital Subscription. The company generates the majority of the revenue from the sale of Connected Fitness Products.
Read more on PTON →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
